Archives of Clinical Infectious Diseases

Published by: Kowsar

Hepatitis B and Hepatitis C in Patients with Inherited Disorders of Hemoglobin in Sistan and Baluchistan Province, Iran

Soheila Khosravi 1 , 2 , Heidar Sharafi 2 , 3 , 4 , Esmaeil Sanei Moghadam 1 , 2 , Fariba Heidari 1 , 2 , Mahmod Naibzadeh 1 , 2 and Seyed Moayed Alavian 2 , 3 , 4 , *
Authors Information
1 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
2 Iran Hepatitis Network, Tehran, Iran
3 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran
4 Middle East Liver Diseases Center, Tehran, Iran
Article information
  • Archives of Clinical Infectious Diseases: 13 (6); e79458
  • Published Online: December 9, 2018
  • Article Type: Research Article
  • Received: May 21, 2018
  • Revised: November 2, 2018
  • Accepted: November 5, 2018
  • DOI: 10.5812/archcid.79458

To Cite: Khosravi S, Sharafi H, Sanei Moghadam E, Heidari F, Naibzadeh M , et al. Hepatitis B and Hepatitis C in Patients with Inherited Disorders of Hemoglobin in Sistan and Baluchistan Province, Iran, Arch Clin Infect Dis. Online ahead of Print ; 13(6):e79458. doi: 10.5812/archcid.79458.

Abstract
Copyright © 2018, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Keshvari M, Hajibeigi B, Azarkeivan A, Keyvani H, Behnava B, Saiedi Hosseini SY, et al. Seroepidemiology of human T-cell lymphotropic virus among Iranian adult thalassemic patients. Transfus Med. 2014;24(4):227-32. doi: 10.1111/tme.12133. [PubMed: 25124072].
  • 2. Prati D, Maggioni M, Milani S, Cerino M, Cianciulli P, Coggi G, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica. 2004;89(10):1179-86. [PubMed: 15477201].
  • 3. Ocak S, Kaya H, Cetin M, Gali E, Ozturk M. Seroprevalence of hepatitis B and hepatitis C in patients with thalassemia and sickle cell anemia in a long-term follow-up. Arch Med Res. 2006;37(7):895-8. doi: 10.1016/j.arcmed.2006.04.007. [PubMed: 16971232].
  • 4. Angelucci E, Pilo F. Treatment of hepatitis C in patients with thalassemia. Haematologica. 2008;93(8):1121-3. doi: 10.3324/haematol.13500. [PubMed: 18669974].
  • 5. Keshvari M, Sharafi H, Alavian SM, Mehrabadi H, Zolfaghari S. Prevalence and trends of transfusion-transmitted infections among blood donors in Tehran, Iran from 2008 to 2013. Transfus Apher Sci. 2015;53(1):38-47. doi: 10.1016/j.transci.2015.03.003. [PubMed: 25892591].
  • 6. Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: A multicenter study. Arch Iran Med. 2006;9(4):319-23. [PubMed: 17061602].
  • 7. Mansouritorghabeh H, Badiei Z. Transfusion-transmitted viruses in individuals with β thalassemia major at Northeastern Iran, a retrospective sero-epidemiological survey. Iran J Blood Cancer. 2008;1(1):1-4.
  • 8. Alavian SM, Tabatabaei SV, Lankarani KB. Epidemiology of HCV infection among thalassemia patients in Eastern Mediterranean countries: A quantitative review of literature. Iran Red Crescent Med J. 2010;12(4):365-76.
  • 9. Miri M, Tabrizi Namini M, Hadipour Dehshal M, Sadeghian Varnosfaderani F, Ahmadvand A, Yousefi Darestani S, et al. Thalassemia in Iran in last twenty years: The carrier rates and the births trend. Iran J Blood Cancer. 2013;6(1):11-7.
  • 10. Salehi-Vaziri M, Sadeghi F, Almasi Hashiani A, Gholami Fesharaki M, Alavian SM. Hepatitis B virus infection in the general population of Iran: An updated systematic review and meta-analysis. Hepat Mon. 2016;16(4). e35577. doi: 10.5812/hepatmon.35577. [PubMed: 27257428]. [PubMed Central: PMC4888501].
  • 11. Sanei Moghaddam E, Rakhshani F, Savad KS. [Prevalence of Hepatitis B and C in patients with major beta-thalassaemia referred to Ali-Asghar Hospital in Zahedan, 1381]. Sci J Iran Blood Transfus Organ. 2004;1(1):19-26. Persian.
  • 12. Samimi-Rad K, Asgari F, Nasiritoosi M, Esteghamati A, Azarkeyvan A, Eslami SM, et al. Patient-to-patient transmission of hepatitis C at Iranian thalassemia centers shown by genetic characterization of viral strains. Hepat Mon. 2013;13(1). e7699. doi: 10.5812/hepatmon.7699. [PubMed: 23585766]. [PubMed Central: PMC3622054].
  • 13. Yousefi M, Dehesh MM, Ebadi M, Dehghan A. The prevalence of hepatitis C virus infection in patients with thalassemia in Zabol city of Iran. Int J Infect. 2017;4(1). doi: 10.17795/iji-37009.
  • 14. Bazi A, Mirimoghaddam E, Rostami D, Dabirzadeh M. Characteristics of seropositive hepatitis B and C thalassemia major patients in South-East of Iran. Biotech Health Sci. 2016;3(2). doi: 10.17795/bhs-35687.
  • 15. Sharafi H, Alavian SM, Behnava B, Pouryasin A, Keshvari M. The impact of IFNL4 rs12979860 polymorphism on spontaneous clearance of hepatitis C; a case-control study. Hepat Mon. 2014;14(10). e22649. doi: 10.5812/hepatmon.22649. [PubMed: 25419220]. [PubMed Central: PMC4238152].
  • 16. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553-62. doi: 10.1038/nrgastro.2013.107. [PubMed: 23817321].
  • 17. Hesamizadeh K, Alavian SM, Najafi Tireh Shabankareh A, Sharafi H. Molecular tracing of hepatitis C virus genotype 1 isolates in Iran: A NS5B phylogenetic analysis with systematic review. Hepat Mon. 2016;16(12). e42938. doi: 10.5812/hepatmon.42938. [PubMed: 28123445]. [PubMed Central: PMC5237473].
  • 18. Ghaderi-Zefrehi H, Gholami-Fesharaki M, Sharafi H, Sadeghi F, Alavian SM. The distribution of hepatitis C virus genotypes in Middle Eastern countries: A systematic review and meta-analysis. Hepat Mon. 2016;16(9). e40357. doi: 10.5812/hepatmon.40357. [PubMed: 27826320]. [PubMed Central: PMC5097177].
  • 19. Kadjbaf D, Keshvari M, Alavian SM, Pouryasin A, Behnava B, Salimi S, et al. The prevalence of hepatitis C virus core amino acid 70 substitution and genotypes of polymorphisms near the IFNL3 gene in Iranian patients with chronic hepatitis C. Hepat Mon. 2016;16(6). e37011. doi: 10.5812/hepatmon.37011. [PubMed: 27630727]. [PubMed Central: PMC5010881].
  • 20. Shahraki T, Shahraki M, Moghaddam ES, Najafi M, Bahari A. Determination of hepatitis C genotypes and the viral titer distribution in children and adolescents with major thalassemia. Iran J Pediatr. 2010;20(1):75-81. [PubMed: 23056686]. [PubMed Central: PMC3445996].
  • 21. Salehi M, Alavian SM, Tabatabaei SV, Izadi S, Sanei Moghaddam E, Amini Kafi-Abad S, et al. Seroepidemiology of HBV infection in South-East of Iran; a population based study. Iran Red Crescent Med J. 2012;14(5):283-8. [PubMed: 22829987]. [PubMed Central: PMC3398635].
  • 22. Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, et al. Recommendations for the clinical management of hepatitis C in Iran: A consensus-based national guideline. Hepat Mon. 2016;16(8). e40959. doi: 10.5812/hepatmon.guideline. [PubMed: 27799966]. [PubMed Central: PMC5075356].
  • 23. Dolatimehr F, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM, Behnava B, Gholami-Fesharaki M, et al. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. Daru. 2017;25(1):11. doi: 10.1186/s40199-017-0177-x. [PubMed: 28427463]. [PubMed Central: PMC5397824].
  • 24. Rezaee-Zavareh MS, Hesamizadeh K, Behnava B, Alavian SM, Gholami-Fesharaki M, Sharafi H. Combination of ledipasvir and sofosbuvir for treatment of hepatitis C virus genotype 1 infection: Systematic review and meta-analysis. Ann Hepatol. 2017;16(2):188-97. doi: 10.5604/16652681.1231562. [PubMed: 28233739].
  • 25. Behnava B, Sharafi H, Keshvari M, Pouryasin A, Mehrnoush L, Salimi S, et al. The role of polymorphisms near the IL28B gene on response to peg-interferon and ribavirin in thalassemic patients with hepatitis C. Hepat Mon. 2016;16(1). e32703. doi: 10.5812/hepatmon.32703. [PubMed: 27110259]. [PubMed Central: PMC4834189].
  • 26. Bristogiannis S, Kattamis A, Kyriakopoulou D, Moraki M, Kountouras D, Alexiou N. the effect of hepatitis C-direct-acting antiviral treatment on the hematogical profile of thalassemic patients. Am Soc Hematol. 2016;128(22):92-5969.
  • 27. Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next steps toward eradication of hepatitis C in the era of direct acting antivirals. Hepat Mon. 2016;16(4). e37089. doi: 10.5812/hepatmon.37089. [PubMed: 27275164]. [PubMed Central: PMC4893415].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments